Clinical Trials Logo

Lynch Syndrome clinical trials

View clinical trials related to Lynch Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04906382 Terminated - Lynch Syndrome Clinical Trials

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient tumors (dMMR) may have difficulty repairing DNA mutations during replication that may affect tumor's response to therapy. Immunotherapy with monoclonal antibodies, such as tislelizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tislelizumab may help treat patients with mismatch repair deficient endometrial cancer.

NCT ID: NCT04508764 Terminated - Lynch Syndrome Clinical Trials

Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome

Start date: April 9, 2021
Phase: N/A
Study type: Interventional

The purpose of this research study is to learn how cancer care providers can help their patients communicate the need for genetic testing in families with inherited cancer syndromes.